It is often difficult to accurately anticipate quality standards across today's global regulatory environments. In recent years, quality expectations have increased as a result of public demand and government regulation while regulatory requirements are often written with limited specificity. Regulations pertaining to parental cell lines (cells engineered to become biotherapeutic production cell lines) is one such area where current regulations leave room for interpretation. Here we explore some important considerations for determining quality standards for parental cell lines.

Cell Line Development

The science of cell line development is a complex balance of investments in platforms, technologies, and personnel to meet the increasing production demands within shortened development timelines. From expression enhancers to high-throughput screening techniques, the laboratory challenges of cell line optimization continue to grow. They now include the need for improving gene delivery and transfection efficiencies, cell productivities, media conditions, cell line stability, and final product quality. Furthermore, companies must incorporate access to intellectual property, technology coordination, and data and information management into an overall program of cell line optimization to satisfy growing requirements for new product development.

(Click to enlarge)

The world market for biotherapeutics is estimated at $80 billion per annum (1), and the number of vaccines produced using biotechnological procedures is growing continuously. Driven by production demands and unmet market needs, scientists have successfully engineered stable cell lines to produce increased yields for a range of biotherapeutics including recombinant proteins and monoclonal antibodies. With the development of new cell lines, these scientists are now challenged to satisfy quality standards for ensuring reproducible and safe cell substrates because the final product quality of biotherapeutics greatly depends on the quality of the cell lines used for their production. This trend to streamline workflows between research and manufacturing has strongly affected the type and scope of cell substrates for in-depth study by biopharmaceutical research teams.

On top of considerations for improving titer and product quality come the dual pressures of speed-to-market and cost reduction. How rapidly and cost-effectively can a concept be turned into a robust cell line? Depending on project complexity, the average time required to generate a stable cell line is six to nine months. As for reducing cost, companies increasingly demand freedom to generate lines exclusive of royalties or licensing fees.

Carefully selecting cell lines that are well-characterized and compatible with production requirements can save a significant amount of development time. As a result, cell line optimization has become a critical but routine step for generating robust and highly productive cells. From drug discovery and cell-based assays to large-scale cell culture for manufacturing, success depends on identifying the right cells that best express the traits you want. Additionally, developing efficient and cost-effective parental cell lines with associated CGMP documentation could play an important role in reducing the downstream risk of adventitious agent contamination, thus streamlining a regulatory package and speeding commercialization of your novel biotherapeutics.

Choosing the Right Cells

Characterizing and testing banked cell substrates are critical to controlling the production of biological products derived from human and animal cell lines. The objective is to confirm the identity, purity, and suitability of cells for manufacturing. Quality concerns for biological products derived from cell lines arise from the possible presence of cellular and adventitious contaminants. Cell banking assures that you have an adequate supply of equivalent, well-characterized cells for production over the expected lifetime of a biotherapeutic product. In addition, cell banking provides the opportunity to undertake a comprehensive characterization of a cell substrate and minimize the likelihood of adventitious agent contamination.

An important part of qualifying a cell line is choosing appropriate testing for the presence of adventitious contaminants. Homogeneity and reproducibility are fundamental requirements of cell banks, so their qualification includes tests for cell identity as well as endogenous and adventitious microbial contaminants (bacteria, fungi, mycoplasma, and viruses). For cells that produce recombinant DNA–based products, analysis of their expression constructs at the nucleic acid level (genetic stability) is also a primary concern. Base your strategy for designing a banked cell safety testing program on sound scientific principles and current regulatory guidance.

After generating cell banks, the most extensive efforts are spent on their quality control. The principles of cell banking and associated safety testing and quality control are addressed by regulatory guidelines for the manufacture of products from animal cell substrates (2,3,4,5).